Prosidyan Announces an Exclusive Joint Collaboration and License Agreement with MO-SCI Corporation for an Exciting New Technology

Warren, NJ, June 30, 2016 –(PR.com)– New Jersey based company Prosidyan, Inc. (www.prosidyan.com), developer of proprietary fiber-based bioactive glass orthobiologics products, announced today that it has entered into an exclusive joint collaboration and license agreement with MO-SCI Corporation of Rolla, Missouri for an exciting new technology involving boron-based bioactive glass materials, for use in the field of human orthopedics, including spinal and trauma applications. Developed at the University of Missouri, this breakthrough platform technology is broad based and is protected by a strong intellectual property portfolio comprising 12 U.S. patents to date. With this partnership, Prosidyan is poised to lead the development of a new generation of bioactive glass products leveraging Aeridyan, the trade name for this advanced boron-based bioactive glass material.

Dr. Hyun Bae, MD, Chief Medical Officer of Prosidyan, commented, “With this next generation of FIBERGRAFT technologies we have added to our leadership position in synthetic bone grafting for spine and orthopedic applications. FIBERGRAFT is an exclusive ultraporous synthetic bone graft that uses proprietary bioactive glass fibers to provide direct connectivity and maximal surface area for HA deposition & an optimized differential rate of resorption. This new advancement represents the next generation in synthetic bone grafting and will enable surgeons to deliver superior outcomes for patients.”

Prosidyan’s President and CEO, Charanpreet Bagga, commented: “This exclusive joint collaboration and license agreement gives us access to new ground breaking intellectual property, which highly compliments our company’s already robust intellectual property portfolio. This allows us not only to work on a next generation synthetic bone graft platform, but also to jump start development of a new load-bearing bioactive synthetic biomaterial.”

Tony Recupero, Prosidyan Advisory Board Member stated, “Prosidyan’s advancements create a product line that exceeds the clinical expectations of surgeons and offers our distribution network a sustainable competitive advantage in the marketplace.”

Prosidyan was founded in 2009 to develop a family of synthetic bioactive bone graft substitutes based on microscopic fibers of bioactive glass. Prosidyan’s flagship product, FIBERGRAFT BG Morsels, a synthetic bone graft substitute, received FDA clearance in March 2014, and the first surgery utilizing this innovative bone substitute was performed in May 2014. The firm’s second product in the line, FIBERGRAFT BG Putty, received FDA clearance in March 2015, and comprises FIBERGRAFT BG Morsels delivered through Prosidyan’s proprietary bioactive carrier, OSSIGLIDE. To date, FIBERGRAFT products have been implanted in over 4,000+ patients across the U.S.

Distribution Opportunities are currently available. Contact Sales@prosidyan.com

About Prosidyan: Prosidyan is the creator and supplier of next generation synthetic bone graft products through its proprietary manufacturing process utilizing microscopic fibers of bioactive glass. For more information about the company and its products, please visit www.prosidyan.com, or call 908.517.3666.